Axsome Therapeutics Inc
Change company Symbol lookup
Select an option...
AXSM Axsome Therapeutics Inc
IVR-B Invesco Mortgage Capital Inc
EWBC East West Bancorp Inc
RVNC Revance Therapeutics Inc
ZFGN Zafgen Inc
SFOR StrikeForce Technologies Inc
SPLV Invesco S&P 500® Low Volatility ETF
USMV iShares Edge MSCI Min Vol USA ETF
HULYX Hawaiian Tax-Free Trust Class Y

Health Care : Pharmaceuticals | Small Cap BlendCompany profile

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Closing Price
Day's Change
-0.38 (-1.51%)
B/A Size
Day's High
Day's Low

10-day average volume:

Occidental acquisition of Anadarko is official, after Chevron drops out of bidding

6:46 pm ET May 9, 2019 (MarketWatch)

Anadarko Petroleum Corp. (APC) said Thursday afternoon that it is officially being acquired by Occidental Petroleum Corp. (OXY), after Chevron Corp. (CVX)declined to counter Occidental's higher bid ( Anadarko officially announced Thursday afternoon that it has agreed to a bid from Occidental that offered $59 in cash and .2934 shares of Occidental for each share of Anadarko. Chevron will receive a $1 billion termination fee from Anadarko. The transaction is expected to close in the second half of the year, Anadarko said. "We are pleased to have reached an agreement with Occidental that delivers significant, near-term value to our shareholders," Anadarko Chief Executive Al Walker said in a statement.

-Jeremy C. Owens; 415-439-6400;

(END) Dow Jones Newswires

May 09, 2019 18:46 ET (22:46 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.